Skip to content

Juvenile Absence Epilepsy C4317339

Published: July 22, 2026Updated: August 25, 2026

A childhood epilepsy syndrome marked by brief periods of unresponsiveness and staring. Commonly affects school-age children. Usually managed effectively with anti-seizure medication.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Brief absence seizures (staring spells)

(neurologic)

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Automatic behaviors (lip smacking)

(neurologic)

Rapid eye blinking

(neurologic)

Postictal confusion

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Anti-Epileptic Drug Therapy

First-line treatment with medications such as ethosuximide, valproic acid, or lamotrigine to control absence seizures through sodium channel or calcium channel modulation.

medication
2

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

EEG Monitoring and Follow-up

Regular electroencephalogram assessments to confirm diagnosis, evaluate treatment response, and detect generalized spike-wave patterns.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Juvenile Absence Epilepsy C4317339?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2012;367(12):1119-1127.

guideline2012
2

Hirsch E, French J, Scheffer IE, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2022;63(4):739-850.

review2022
3

Matsuo M, Toda Y, Hata D, et al. Long-term outcomes of ethosuximide treatment in juvenile absence epilepsy: A systematic review and meta-analysis. Epilepsy Res. 2020;166:106404.

meta_analysis2020
4

Bazil CW, Walczak TS. Juvenile absence epilepsy and eyelid myoclonia. J Clin Neurophysiol. 2017;34(3):235-240.

other2017

Medication Comparisons

Compare medications used to treat Juvenile Absence Epilepsy C4317339. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy